Association of gut microbiome dysbiosis with the progression of atrial fibrillation: A systematic review

Abstract

AbstractObjectiveMany clinical and preclinical studies have implicated an association between atrial fibrillation (AF) and its progression to imbalances in the gut microbiome composition. The gut microbiome is a diverse and complex ecosystem containing billions of microorganisms that produce biologically active metabolites influencing the host disease development.MethodsFor this review, a literature search was conducted using digital databases to systematically identify the studies reporting the association of gut microbiota with AF progression.ResultsIn a total of 14 studies, 2479 patients were recruited for the final analysis. More than half (n = 8) of the studies reported alterations in alpha diversity in atrial fibrillation. As for the beta diversity, 10 studies showed significant alterations. Almost all studies that assessed gut microbiota alterations reported major taxa associated with atrial fibrillation. Most studies focused on short‐chain fatty acids (SCFAs), whereas three studies evaluated TMAO levels in the blood, which is the breakdown product of dietary l‐carnitine, choline, and lecithin. Moreover, an independent cohort study assessed the relationship between phenylacetylglutamine (PAGIn) and AF.ConclusionIntestinal dysbiosis is a modifiable risk factor that might provide newer treatment strategies for AF prevention. Well‐designed research and prospective randomized interventional studies are required to target the gut dysbiotic mechanisms and determine the gut dysbiotic‐AF relationship.